Literature DB >> 15698430

Pathways of caspase-mediated apoptosis in autosomal-dominant polycystic kidney disease (ADPKD).

Yunxia Tao1, Jun Kim, Melinda Stanley, Zhibin He, Sarah Faubel, Robert W Schrier, Charles L Edelstein.   

Abstract

BACKGROUND: We have recently demonstrated an increase in apoptosis in Han:SPRD rat kidneys with autosomal-dominant polycystic kidney disease (ADPKD). Caspase-3 and caspase-7 are major mediators of apoptosis. There are two pathways of caspase-3 and caspase-7-mediated apoptosis: (1) the "extrinsic" pathway involving the death receptor Fas, Fas ligand (FasL), and caspase-8 and (2) the "mitochondrial" or "intrinsic" pathway involving Bcl-2 proteins, caspase-2, cytochrome c release, and caspase-9. The aim of the present study was to investigate the pathways of apoptosis in 3-week-old Han:SPRD rats with ADPKD.
METHODS: Fluorescent substrates were used to measure caspase activity. mRNA and protein was determined by ribonuclease protection assays and immunoblotting, respectively. The effect of caspase inhibitors on caspase activity in polycystic kidneys was determined.
RESULTS: Caspase-3 and caspase-7 activity was more than 100% increased in homozygous (Cy/Cy) compared to heterozygous (Cy/+) and normal littermate control (+/+) kidneys. Ribonuclease protection assays demonstrated no difference in caspase-3 mRNA. On immunoblotting, there was an increase in the proform of caspase-3 and caspase-7 in Cy/Cy compared to +/+ and Cy/+ kidneys. Caspase-8 and caspase-9 activity was more than 100% increased in Cy/Cy compared to Cy/+ and +/+ kidneys. On immunoblotting, there was an increase of the proform of both caspase-8 and caspase-9 in Cy/Cy kidneys. There was also an increase in cytochrome c release into the cytosol and an increase in caspase-2 protein and activity in Cy/Cy kidneys. On ribonuclease protection assay there was no difference in FasL mRNA between +/+, Cy/+, and Cy/Cy kidneys. Short-term treatment of Cy/Cy rats with the caspase inhibitor IDN-8050 resulted in inhibition of caspase-3 and caspase-7 activity in the kidney.
CONCLUSION: In Cy/Cy kidneys with ADPKD, there was an increase of the proform of caspase-9, an increase in cytochrome c release into the cytosol, and an increase in caspase-2 protein and activity demonstrating involvement of the intrinsic pathway. There was an increase in the proform of caspase-8 demonstrating involvement of the extrinsic pathway. No differences in FasL mRNA were seen suggesting that the extrinsic pathway is independent of the death receptor ligand, FasL.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15698430     DOI: 10.1111/j.1523-1755.2005.00155.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  16 in total

1.  Hypoxia-inducible factor-1α (HIF-1α) and autophagy in polycystic kidney disease (PKD).

Authors:  Franck Belibi; Iram Zafar; Kameswaran Ravichandran; Anamarija Bauer Segvic; Alkesh Jani; Danica Galesic Ljubanovic; Charles L Edelstein
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-26

2.  Loss of PKD1 and loss of Bcl-2 elicit polycystic kidney disease through distinct mechanisms.

Authors:  P Hughes; M Robati; W Lu; J Zhou; A Strasser; P Bouillet
Journal:  Cell Death Differ       Date:  2005-11-11       Impact factor: 15.828

Review 3.  Potential pharmacological interventions in polycystic kidney disease.

Authors:  Amirali Masoumi; Berenice Reed-Gitomer; Catherine Kelleher; Robert W Schrier
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Caspase-3 gene deletion prolongs survival in polycystic kidney disease.

Authors:  Yunxia Tao; Iram Zafar; Jun Kim; Robert W Schrier; Charles L Edelstein
Journal:  J Am Soc Nephrol       Date:  2008-02-13       Impact factor: 10.121

5.  Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease.

Authors:  Yunxia Tao; Jun Kim; Sarah Faubel; Joe C Wu; Sandor A Falk; Robert W Schrier; Charles L Edelstein
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-29       Impact factor: 11.205

6.  Chronic treatment with lisinopril decreases proliferative and apoptotic pathways in autosomal recessive polycystic kidney disease.

Authors:  Guangfu Jia; Michelle Kwon; Huan Ling Liang; Jordan Mortensen; Vani Nilakantan; William E Sweeney; Frank Park
Journal:  Pediatr Nephrol       Date:  2010-03-13       Impact factor: 3.714

Review 7.  Emerging therapies for chronic kidney disease: what is their role?

Authors:  Eswari Vilayur; David C H Harris
Journal:  Nat Rev Nephrol       Date:  2009-05-19       Impact factor: 28.314

8.  Pathways of apoptosis in human autosomal recessive and autosomal dominant polycystic kidney diseases.

Authors:  Beatrice Goilav; Lisa M Satlin; Patricia D Wilson
Journal:  Pediatr Nephrol       Date:  2008-05-31       Impact factor: 3.714

9.  Apoptosis and autophagy in polycystic kidney disease (PKD).

Authors:  Kristen L Nowak; Charles L Edelstein
Journal:  Cell Signal       Date:  2019-12-24       Impact factor: 4.315

Review 10.  Mining the Biomarker Potential of the Urine Peptidome: From Amino Acids Properties to Proteases.

Authors:  Fábio Trindade; António S Barros; Jéssica Silva; Antonia Vlahou; Inês Falcão-Pires; Sofia Guedes; Carla Vitorino; Rita Ferreira; Adelino Leite-Moreira; Francisco Amado; Rui Vitorino
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.